[Recommendations for the medical management of aortic complications of Marfan's syndrome].
Jondeau
Guillaume
G
Hôpital Ambroise Paré, Boulogne.
Barthelet
Martine
M
Baumann
Clarisse
C
Bonnet
Damien
D
Chevallier
Bertrand
B
Collignon
Patrick
P
Dulac
Yves
Y
Edouard
Thomas
T
Faivre
Laurence
L
Germain
Dominique
D
Khau Van Kien
Philipe
P
Lacombe
Didier
D
Ladouceur
Magalie
M
Lemerrer
Martine
M
Leheup
Bruno
B
Lupoglazoff
Jean-Marc
JM
Magnier
Suzel
S
Muti
Christine
C
Plauchu
Pr Henri
PH
Raffestin
Bernadette
B
Sassolas
F
F
Schleich
Jean-Marc
JM
Sidi
Daniel
D
Themar-Noël
Christine
C
Varin
Jean
J
Wolf
Jean-Eric
JE
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000784:Aortic Dissection / Q000517:prevention & control*; D001014:Aortic Aneurysm / Q000517:prevention & control*; D001262:Atenolol / Q000627:therapeutic use; D017298:Bisoprolol / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005602:France; D006801:Humans; D008382:Marfan Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D012955:Societies, Medical; D016896:Treatment Outcome; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D001262:Atenolol; D014700:Verapamil; D017298:Bisoprolol